{"product_id":"chondrosulf-chondroitin-800mg-90-tablets","title":"Chondrosulf Chondroitin 800mg – 90 Tablets","description":"\u003cp data-end=\"329\" data-start=\"65\"\u003e\u003cstrong data-end=\"89\" data-start=\"65\"\u003eProduct Description:\u003c\/strong\u003e\u003cbr data-end=\"92\" data-start=\"89\"\u003eChondrosulf 800mg is an over-the-counter medicine containing chondroitin sulfate. It is used as a delayed-action symptomatic treatment for osteoarthritis in adults, including osteoarthritis of the hip, knee, and small joints of the hand.\u003c\/p\u003e\n\u003cp data-end=\"520\" data-start=\"331\"\u003eChondroitin helps support joint comfort and mobility over time. The effect is not immediate and may take up to 2 months to become noticeable. Benefits may continue after stopping treatment.\u003c\/p\u003e\n\u003cp data-end=\"755\" data-start=\"522\"\u003e\u003cstrong data-end=\"535\" data-start=\"522\"\u003eBenefits:\u003c\/strong\u003e\u003cbr data-end=\"538\" data-start=\"535\"\u003eSupports joint comfort in osteoarthritis\u003cbr data-end=\"581\" data-start=\"578\"\u003eHelps improve mobility over time\u003cbr data-end=\"616\" data-start=\"613\"\u003eSuitable for osteoarthritis of the hip, knee, and small joints of the hand\u003cbr data-end=\"693\" data-start=\"690\"\u003eOnce-daily tablet format\u003cbr data-end=\"720\" data-start=\"717\"\u003eNon-prescription medicine in France\u003c\/p\u003e\n\u003cp data-end=\"893\" data-start=\"757\"\u003e\u003cstrong data-end=\"777\" data-start=\"757\"\u003eRecommended Use:\u003c\/strong\u003e\u003cbr data-end=\"780\" data-start=\"777\"\u003eAdults over 18 years: Take 1 tablet per day with a glass of water.\u003cbr data-end=\"849\" data-start=\"846\"\u003eMay be taken before, during, or after meals.\u003c\/p\u003e\n\u003cp data-end=\"1208\" data-start=\"895\"\u003e\u003cstrong data-end=\"921\" data-start=\"895\"\u003eImportant Information:\u003c\/strong\u003e\u003cbr data-end=\"924\" data-start=\"921\"\u003eNot recommended for children or adolescents under 18 years old.\u003cbr data-end=\"990\" data-start=\"987\"\u003eNot recommended during pregnancy or breastfeeding.\u003cbr data-end=\"1043\" data-start=\"1040\"\u003eMay cause side effects in some people, including skin rash or digestive discomfort. Consult your doctor if you have any concerns.\u003cbr data-end=\"1175\" data-start=\"1172\"\u003eContains sodium: 73mg per tablet.\u003c\/p\u003e\n\u003cp data-end=\"1278\" data-start=\"1210\"\u003e\u003cstrong data-end=\"1232\" data-start=\"1210\"\u003eActive Ingredient:\u003c\/strong\u003e\u003cbr data-end=\"1235\" data-start=\"1232\"\u003eChondroitin sulfate sodium 800mg per tablet\u003c\/p\u003e\n\u003cp data-end=\"1310\" data-start=\"1280\"\u003e\u003cstrong data-end=\"1297\" data-start=\"1280\"\u003ePackage Size:\u003c\/strong\u003e\u003cbr data-end=\"1300\" data-start=\"1297\"\u003e90 tablets\u003c\/p\u003e\n\u003cp data-end=\"1329\" data-start=\"1312\"\u003e\u003cstrong data-end=\"1322\" data-start=\"1312\"\u003eBrand:\u003c\/strong\u003e\u003cbr data-end=\"1325\" data-start=\"1322\"\u003eIBSA\u003c\/p\u003e\n\u003cp data-end=\"1367\" data-start=\"1331\"\u003e\u003cstrong data-end=\"1351\" data-start=\"1331\"\u003eEAN \/ Reference:\u003c\/strong\u003e\u003cbr data-end=\"1354\" data-start=\"1351\"\u003e3400930281185\u003c\/p\u003e\n\u003cp data-end=\"1438\" data-start=\"1369\"\u003e\u003cstrong data-end=\"1386\" data-start=\"1369\"\u003eProduct Type:\u003c\/strong\u003e\u003cbr data-end=\"1389\" data-start=\"1386\"\u003eOsteoarthritis treatment \/ joint comfort medicine\u003c\/p\u003e\n\u003ch2 data-end=\"72\" data-start=\"35\" data-section-id=\"n7fa2t\"\u003eSummary of Product Characteristics\u003c\/h2\u003e\n\u003cp data-end=\"104\" data-start=\"74\"\u003e\u003cstrong data-end=\"104\" data-start=\"74\"\u003eANSM – Updated: 10\/26\/2023\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"141\" data-start=\"106\" data-section-id=\"10od4yy\"\u003e1. Name of the Medicinal Product\u003c\/h2\u003e\n\u003cp data-end=\"173\" data-start=\"143\"\u003e\u003cstrong data-end=\"173\" data-start=\"143\"\u003eCHONDROSULF 800 mg, tablet\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"221\" data-start=\"175\" data-section-id=\"3kvysc\"\u003e2. Qualitative and Quantitative Composition\u003c\/h2\u003e\n\u003cp data-end=\"274\" data-start=\"223\"\u003e\u003cstrong data-end=\"254\" data-start=\"223\"\u003eChondroitin sulfate sodium:\u003c\/strong\u003e 800 mg\u003cbr data-end=\"264\" data-start=\"261\"\u003ePer tablet\u003c\/p\u003e\n\u003cp data-end=\"329\" data-start=\"276\"\u003eExcipient with known effect: sodium 73 mg per tablet.\u003c\/p\u003e\n\u003cp data-end=\"380\" data-start=\"331\"\u003eFor the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003ch2 data-end=\"407\" data-start=\"382\" data-section-id=\"vohs2x\"\u003e3. Pharmaceutical Form\u003c\/h2\u003e\n\u003cp data-end=\"416\" data-start=\"409\"\u003eTablet.\u003c\/p\u003e\n\u003cp data-end=\"465\" data-start=\"418\"\u003eWhite to almost white, oblong, biconvex tablet.\u003c\/p\u003e\n\u003ch2 data-end=\"493\" data-start=\"467\" data-section-id=\"clrtzw\"\u003e4. Clinical Information\u003c\/h2\u003e\n\u003ch3 data-end=\"526\" data-start=\"495\" data-section-id=\"4ljgym\"\u003e4.1 Therapeutic Indications\u003c\/h3\u003e\n\u003cp data-end=\"648\" data-start=\"528\"\u003eDelayed-action symptomatic treatment of osteoarthritis of the hip, knee, and small joints of the hand in adult patients.\u003c\/p\u003e\n\u003ch3 data-end=\"693\" data-start=\"650\" data-section-id=\"1brtoli\"\u003e4.2 Dosage and Method of Administration\u003c\/h3\u003e\n\u003cp data-end=\"730\" data-start=\"695\"\u003eFor adults only, over 18 years old.\u003c\/p\u003e\n\u003cp data-end=\"772\" data-start=\"732\"\u003e\u003cstrong data-end=\"742\" data-start=\"732\"\u003eDosage\u003c\/strong\u003e\u003cbr data-end=\"745\" data-start=\"742\"\u003e1 tablet of 800 mg per day.\u003c\/p\u003e\n\u003cp data-end=\"942\" data-start=\"774\"\u003e\u003cstrong data-end=\"798\" data-start=\"774\"\u003ePediatric Population\u003c\/strong\u003e\u003cbr data-end=\"801\" data-start=\"798\"\u003eDue to the absence of clinical data, the use of chondroitin sulfate sodium in children and adolescents under 18 years old is not recommended.\u003c\/p\u003e\n\u003cp data-end=\"984\" data-start=\"944\"\u003e\u003cstrong data-end=\"972\" data-start=\"944\"\u003eMethod of Administration\u003c\/strong\u003e\u003cbr data-end=\"975\" data-start=\"972\"\u003eOral use.\u003c\/p\u003e\n\u003cp data-end=\"1039\" data-start=\"986\"\u003eThe tablet should be swallowed with a glass of water.\u003c\/p\u003e\n\u003cp data-end=\"1146\" data-start=\"1041\"\u003e\u003cstrong data-end=\"1072\" data-start=\"1041\"\u003eFrequency of Administration\u003c\/strong\u003e\u003cbr data-end=\"1075\" data-start=\"1072\"\u003eCHONDROSULF 800 mg tablets may be taken before, during, or after meals.\u003c\/p\u003e\n\u003cp data-end=\"1355\" data-start=\"1148\"\u003e\u003cstrong data-end=\"1178\" data-start=\"1148\"\u003eDuration of Administration\u003c\/strong\u003e\u003cbr data-end=\"1181\" data-start=\"1178\"\u003eThe duration of treatment should be adjusted according to clinical results, keeping in mind that the effect is delayed by 2 months and may persist after treatment is stopped.\u003c\/p\u003e\n\u003ch3 data-end=\"1382\" data-start=\"1357\" data-section-id=\"idzai5\"\u003e4.3 Contraindications\u003c\/h3\u003e\n\u003cp data-end=\"1444\" data-start=\"1384\"\u003eThis medicine is contraindicated in the following situation:\u003c\/p\u003e\n\u003cp data-end=\"1537\" data-start=\"1446\"\u003eHypersensitivity to the active substance or to any of the excipients listed in section 6.1.\u003c\/p\u003e\n\u003ch3 data-end=\"1587\" data-start=\"1539\" data-section-id=\"1c98jg\"\u003e4.4 Special Warnings and Precautions for Use\u003c\/h3\u003e\n\u003cp data-end=\"1683\" data-start=\"1589\"\u003eThis medicine is not intended for children or adolescents under 18 years old. See section 4.2.\u003c\/p\u003e\n\u003cp data-end=\"1769\" data-start=\"1685\"\u003eThis medicine is not recommended during pregnancy or breastfeeding. See section 4.6.\u003c\/p\u003e\n\u003cp data-end=\"2152\" data-start=\"1771\"\u003e\u003cstrong data-end=\"1817\" data-start=\"1771\"\u003ePatients with heart and\/or kidney failure:\u003c\/strong\u003e\u003cbr data-end=\"1820\" data-start=\"1817\"\u003eIn very rare cases, less than 1 in 10,000, edema and\/or water retention have been reported in patients treated with chondroitin sulfate sodium. This may be attributed to the osmotic effect of chondroitin sulfate sodium. In patients with kidney and\/or heart failure, this medicine should be used with caution and monitored regularly.\u003c\/p\u003e\n\u003cp data-end=\"2360\" data-start=\"2154\"\u003e\u003cstrong data-end=\"2186\" data-start=\"2154\"\u003ePatients with liver failure:\u003c\/strong\u003e\u003cbr data-end=\"2189\" data-start=\"2186\"\u003eNo data are available on the use of chondroitin sulfate sodium in patients with liver failure. Therefore, the medicine should be used with caution and monitored regularly.\u003c\/p\u003e\n\u003cp data-end=\"2503\" data-start=\"2362\"\u003eThis medicine contains 73 mg of sodium per tablet, equivalent to 3.8% of the WHO recommended maximum daily intake of 2 g sodium for an adult.\u003c\/p\u003e\n\u003ch3 data-end=\"2577\" data-start=\"2505\" data-section-id=\"r4t6rs\"\u003e4.5 Interactions with Other Medicines and Other Forms of Interaction\u003c\/h3\u003e\n\u003cp data-end=\"2622\" data-start=\"2579\"\u003eNo interaction studies have been performed.\u003c\/p\u003e\n\u003ch3 data-end=\"2671\" data-start=\"2624\" data-section-id=\"vex3lb\"\u003e4.6 Fertility, Pregnancy, and Breastfeeding\u003c\/h3\u003e\n\u003cp data-end=\"2981\" data-start=\"2673\"\u003e\u003cstrong data-end=\"2686\" data-start=\"2673\"\u003ePregnancy\u003c\/strong\u003e\u003cbr data-end=\"2689\" data-start=\"2686\"\u003eThere are no clinical data on the administration of this product during pregnancy. Animal studies are insufficient to determine effects on reproduction and embryonic, fetal, and postnatal development. See section 5.3. The use of CHONDROSULF 800 mg tablets is not recommended during pregnancy.\u003c\/p\u003e\n\u003cp data-end=\"3141\" data-start=\"2983\"\u003e\u003cstrong data-end=\"3000\" data-start=\"2983\"\u003eBreastfeeding\u003c\/strong\u003e\u003cbr data-end=\"3003\" data-start=\"3000\"\u003eDue to the absence of data on excretion into breast milk, the use of CHONDROSULF 800 mg tablets is not recommended in breastfeeding women.\u003c\/p\u003e\n\u003cp data-end=\"3241\" data-start=\"3143\"\u003e\u003cstrong data-end=\"3156\" data-start=\"3143\"\u003eFertility\u003c\/strong\u003e\u003cbr data-end=\"3159\" data-start=\"3156\"\u003eAnimal studies are insufficient to determine effects on male and female fertility.\u003c\/p\u003e\n\u003ch3 data-end=\"3295\" data-start=\"3243\" data-section-id=\"7d464l\"\u003e4.7 Effects on Ability to Drive and Use Machines\u003c\/h3\u003e\n\u003cp data-end=\"3381\" data-start=\"3297\"\u003eThe effects on the ability to drive vehicles and use machines have not been studied.\u003c\/p\u003e\n\u003cp data-end=\"3480\" data-start=\"3383\"\u003eChondroitin sulfate has no or negligible effect on the ability to drive vehicles or use machines.\u003c\/p\u003e\n\u003ch3 data-end=\"3509\" data-start=\"3482\" data-section-id=\"12x45fc\"\u003e4.8 Undesirable Effects\u003c\/h3\u003e\n\u003cp data-end=\"3847\" data-start=\"3511\"\u003eUndesirable effects are classified within each system organ class and by frequency using the following convention: very common, more than 1 in 10; common, at least 1 in 100 and less than 1 in 10; uncommon, at least 1 in 1,000 and less than 1 in 100; rare, at least 1 in 10,000 and less than 1 in 1,000; very rare, less than 1 in 10,000.\u003c\/p\u003e\n\u003cp data-end=\"3900\" data-start=\"3849\"\u003e\u003cstrong data-end=\"3877\" data-start=\"3849\"\u003eNervous system disorders\u003c\/strong\u003e\u003cbr data-end=\"3880\" data-start=\"3877\"\u003eVery rare: dizziness\u003c\/p\u003e\n\u003cp data-end=\"4002\" data-start=\"3902\"\u003e\u003cstrong data-end=\"3932\" data-start=\"3902\"\u003eGastrointestinal disorders\u003c\/strong\u003e\u003cbr data-end=\"3935\" data-start=\"3932\"\u003eRare: gastrointestinal disorders, epigastric pain, nausea, diarrhea\u003c\/p\u003e\n\u003cp data-end=\"4137\" data-start=\"4004\"\u003e\u003cstrong data-end=\"4046\" data-start=\"4004\"\u003eSkin and subcutaneous tissue disorders\u003c\/strong\u003e\u003cbr data-end=\"4049\" data-start=\"4046\"\u003eRare: erythema, rash, maculopapular rash, urticaria, eczema, itching, allergic reaction¹\u003c\/p\u003e\n\u003cp data-end=\"4215\" data-start=\"4139\"\u003e\u003cstrong data-end=\"4195\" data-start=\"4139\"\u003eGeneral disorders and administration site conditions\u003c\/strong\u003e\u003cbr data-end=\"4198\" data-start=\"4195\"\u003eVery rare: edema²\u003c\/p\u003e\n\u003cp data-end=\"4315\" data-start=\"4217\"\u003e¹ Cases of allergic reactions, such as angioedema, have been rarely observed.\u003cbr data-end=\"4297\" data-start=\"4294\"\u003e² See section 4.4.\u003c\/p\u003e\n\u003cp data-end=\"4807\" data-start=\"4317\"\u003e \u003c\/p\u003e\n\u003ch3 data-end=\"4825\" data-start=\"4809\" data-section-id=\"1xn8bp2\"\u003e4.9 Overdose\u003c\/h3\u003e\n\u003cp data-end=\"5034\" data-start=\"4827\"\u003eNo clinical or biological signs are expected in the event of massive ingestion of CHONDROSULF 800 mg tablets. However, if adverse effects related to overdose occur, symptomatic treatment should be initiated.\u003c\/p\u003e\n\u003ch2 data-end=\"5068\" data-start=\"5036\" data-section-id=\"87n1h3\"\u003e5. Pharmacological Properties\u003c\/h2\u003e\n\u003ch3 data-end=\"5104\" data-start=\"5070\" data-section-id=\"18ze1xv\"\u003e5.1 Pharmacodynamic Properties\u003c\/h3\u003e\n\u003cp data-end=\"5226\" data-start=\"5106\"\u003e\u003cstrong data-end=\"5136\" data-start=\"5106\"\u003ePharmacotherapeutic class:\u003c\/strong\u003e Other anti-inflammatory and antirheumatic products, non-steroidal\u003cbr data-end=\"5205\" data-start=\"5202\"\u003e\u003cstrong data-end=\"5218\" data-start=\"5205\"\u003eATC code:\u003c\/strong\u003e M01AX25\u003c\/p\u003e\n\u003cp data-end=\"5418\" data-start=\"5228\"\u003e\u003cstrong data-end=\"5251\" data-start=\"5228\"\u003eMechanism of Action\u003c\/strong\u003e\u003cbr data-end=\"5254\" data-start=\"5251\"\u003eChondroitin sulfate sodium, the active ingredient in CHONDROSULF 800 mg tablets, belongs to the subgroup of polysaccharides included in the glycosaminoglycan group.\u003c\/p\u003e\n\u003cp data-end=\"5623\" data-start=\"5420\"\u003eChondroitin sulfate sodium is one of the main components of cartilage. It binds to a central protein, forming what is known as a proteoglycan, which gives cartilage its mechanical and elastic properties.\u003c\/p\u003e\n\u003cp data-end=\"6243\" data-start=\"5625\"\u003e\u003cstrong data-end=\"5652\" data-start=\"5625\"\u003ePharmacodynamic Effects\u003c\/strong\u003e\u003cbr data-end=\"5655\" data-start=\"5652\"\u003eThe therapeutic effect of chondroitin sulfate sodium in patients with osteoarthritis is due to anti-inflammatory activity at the level of the cellular components of inflammation in vivo, stimulation of the synthesis of endogenous proteoglycans in vitro and hyaluronic acid in vivo, and a decrease in the catabolic activity of chondrocytes in vivo. It inhibits certain proteolytic enzymes, including collagenase, elastase, proteoglycanases, phospholipase A2, N-acetyl-glucosaminidase, etc., in vitro and in vivo, as well as the formation of other substances that damage cartilage in vitro.\u003c\/p\u003e\n\u003cp data-end=\"6393\" data-start=\"6245\"\u003eIn vitro, chondroitin sulfate inhibits elastase, a mediator of cartilage degradation. It stimulates proteoglycan synthesis by cultured chondrocytes.\u003c\/p\u003e\n\u003cp data-end=\"6575\" data-start=\"6395\"\u003e\u003cstrong data-end=\"6427\" data-start=\"6395\"\u003eClinical Efficacy and Safety\u003c\/strong\u003e\u003cbr data-end=\"6430\" data-start=\"6427\"\u003eCHONDROSULF 800 mg tablets were studied in two pivotal clinical trials in osteoarthritis of the knee and hand, including a total of 766 patients.\u003c\/p\u003e\n\u003cp data-end=\"6800\" data-start=\"6577\"\u003eThe pivotal knee osteoarthritis study was conducted to evaluate the efficacy and safety of CHONDROSULF 800 mg tablets versus celecoxib 200 mg and placebo in patients with knee osteoarthritis over a 6-month treatment period.\u003c\/p\u003e\n\u003cp data-end=\"7002\" data-start=\"6802\"\u003eThe results of this study showed that at 800 mg\/day, chondroitin sulfate was superior to placebo in reducing pain and improving mobility over 6 months in patients with symptomatic knee osteoarthritis.\u003c\/p\u003e\n\u003cp data-end=\"7352\" data-start=\"7004\"\u003eThe pivotal hand osteoarthritis study was conducted to evaluate the efficacy and safety of CHONDROSULF 800 mg tablets versus placebo in patients with radiologically confirmed finger joint osteoarthritis over a 6-month treatment period. The results showed that chondroitin sulfate was superior to placebo in improving overall pain and hand mobility.\u003c\/p\u003e\n\u003cp data-end=\"7471\" data-start=\"7354\"\u003eSafety results from clinical studies showed that CHONDROSULF 800 mg tablets have a safety profile similar to placebo.\u003c\/p\u003e\n\u003cp data-end=\"7528\" data-start=\"7473\"\u003eOther studies also confirm safety over a longer period.\u003c\/p\u003e\n\u003cp data-end=\"8166\" data-start=\"7530\"\u003eTwo additional randomized phase 3 clinical studies conducted over two years showed no differences between chondroitin sulfate 800 mg\/day and placebo groups in the frequency of adverse effects among 922 patients with knee osteoarthritis. Both studies demonstrated maintenance of joint space after 2 years of treatment with chondroitin sulfate 800 mg compared with placebo. There is not enough information on the long-term effect of chondroitin on radiographic progression, but based on these two studies, chondroitin sulfate may have an effect on maintaining joint space in patients with knee osteoarthritis after two years of treatment.\u003c\/p\u003e\n\u003cp data-end=\"8926\" data-start=\"8168\"\u003eIn both studies, pain reduction was evaluated as a secondary endpoint. In one study, there was no appreciable change in pain, measured using the WOMAC pain scale, over two years. The most likely reason for this result was the relatively low average pain score of subjects at study entry, which left little room for improvement. In the second study, no significant difference in pain between chondroitin sulfate and placebo was observed during the second year of the study. However, differences in reduced pain scores using the VAS scale between the two groups, in favor of chondroitin sulfate, were significant between months 1 and 9, confirming results from other shorter published studies of 3 to 6 months on the symptomatic effects of chondroitin sulfate.\u003c\/p\u003e\n\u003ch3 data-end=\"8962\" data-start=\"8928\" data-section-id=\"mmekky\"\u003e5.2 Pharmacokinetic Properties\u003c\/h3\u003e\n\u003cp data-end=\"9578\" data-start=\"8964\"\u003e\u003cstrong data-end=\"8978\" data-start=\"8964\"\u003eAbsorption\u003c\/strong\u003e\u003cbr data-end=\"8981\" data-start=\"8978\"\u003eSeveral studies indicate that the bioavailability of chondroitin sulfate sodium ranges from 15% to 20% of the orally administered dose. Ten percent of the absorbed portion of chondroitin sulfate sodium appears as chondroitin sulfate and 90% as depolymerized derivatives of lower molecular weight, suggesting a first-pass hepatic effect. After oral administration of chondroitin sulfate sodium, the maximum blood concentration is reached in approximately 2 to 4 hours, with a slightly shorter time to maximum concentration when taken on an empty stomach. Steady state is reached after 3 to 4 hours.\u003c\/p\u003e\n\u003cp data-end=\"10375\" data-start=\"9580\"\u003e\u003cstrong data-end=\"9596\" data-start=\"9580\"\u003eDistribution\u003c\/strong\u003e\u003cbr data-end=\"9599\" data-start=\"9596\"\u003eThe volume of distribution of chondroitin sulfate sodium is relatively low, around 0.4 L\/kg. In humans, 24 hours after oral administration, a high concentration of the substance may be found in the wall of the small intestine, liver, brain, and kidneys compared with other tissues. Chondroitin sulfate has been shown to be elevated not only in these organs involved in the breakdown and excretion of oligo- and polysaccharides, but also in synovial fluid and cartilage, where the molecule tends to accumulate. Reports have shown a very low percentage of protein binding, only 0.23% of total proteins. Reports have shown significant accumulation of the compound in synovial fluids, where chondroitin sulfate sodium exerts its chondroprotective and anti-inflammatory activities.\u003c\/p\u003e\n\u003cp data-end=\"10624\" data-start=\"10377\"\u003e\u003cstrong data-end=\"10398\" data-start=\"10377\"\u003eBiotransformation\u003c\/strong\u003e\u003cbr data-end=\"10401\" data-start=\"10398\"\u003eAbsorbed concentrations of chondroitin sulfate sodium reach the blood compartment as chondroitin sulfate 10% and depolymerized low-molecular-weight derivatives 90%. Chondroitin sulfate is not metabolized by cytochrome P450.\u003c\/p\u003e\n\u003cp data-end=\"11140\" data-start=\"10626\"\u003e\u003cstrong data-end=\"10641\" data-start=\"10626\"\u003eElimination\u003c\/strong\u003e\u003cbr data-end=\"10644\" data-start=\"10641\"\u003eChondroitin sulfate sodium, both as an intact polymer and as depolymerized derivatives, is mainly eliminated by the kidneys. After oral administration, approximately 15% of the administered dose is excreted in the urine during the first 48 hours. The average elimination half-life after oral administration of chondroitin sulfate sodium is approximately 5 hours, varying from 5 to 10 hours depending on the experimental protocol. The systemic clearance of chondroitin sulfate sodium is 20 mL\/min.\u003c\/p\u003e\n\u003ch3 data-end=\"11173\" data-start=\"11142\" data-section-id=\"13rpa96\"\u003e5.3 Preclinical Safety Data\u003c\/h3\u003e\n\u003cp data-end=\"11314\" data-start=\"11175\"\u003eNon-clinical data reveal no particular hazard for humans based on repeated-dose toxicity, genotoxicity, and carcinogenic potential studies.\u003c\/p\u003e\n\u003cp data-end=\"11448\" data-start=\"11316\"\u003eThe animal data available to date do not allow assessment of the effect of CHONDROSULF 800 mg tablets on fertility and reproduction.\u003c\/p\u003e\n\u003ch2 data-end=\"11482\" data-start=\"11450\" data-section-id=\"p23c2e\"\u003e6. Pharmaceutical Information\u003c\/h2\u003e\n\u003ch3 data-end=\"11510\" data-start=\"11484\" data-section-id=\"1pmqv3a\"\u003e6.1 List of Excipients\u003c\/h3\u003e\n\u003cp data-end=\"11531\" data-start=\"11512\"\u003eMagnesium stearate.\u003c\/p\u003e\n\u003ch3 data-end=\"11558\" data-start=\"11533\" data-section-id=\"1svkhc3\"\u003e6.2 Incompatibilities\u003c\/h3\u003e\n\u003cp data-end=\"11575\" data-start=\"11560\"\u003eNot applicable.\u003c\/p\u003e\n\u003ch3 data-end=\"11595\" data-start=\"11577\" data-section-id=\"1avu3lr\"\u003e6.3 Shelf Life\u003c\/h3\u003e\n\u003cp data-end=\"11605\" data-start=\"11597\"\u003e3 years.\u003c\/p\u003e\n\u003ch3 data-end=\"11646\" data-start=\"11607\" data-section-id=\"126jy7q\"\u003e6.4 Special Precautions for Storage\u003c\/h3\u003e\n\u003cp data-end=\"11679\" data-start=\"11648\"\u003eNo special storage precautions.\u003c\/p\u003e\n\u003ch3 data-end=\"11721\" data-start=\"11681\" data-section-id=\"1mobozx\"\u003e6.5 Nature and Contents of Container\u003c\/h3\u003e\n\u003cp data-end=\"11785\" data-start=\"11723\"\u003ePolyamide-Aluminum-PVC \/ thermolacquer-Aluminum blister packs.\u003c\/p\u003e\n\u003cp data-end=\"11811\" data-start=\"11787\"\u003eBox of 30 or 90 tablets.\u003c\/p\u003e\n\u003cp data-end=\"11848\" data-start=\"11813\"\u003eNot all pack sizes may be marketed.\u003c\/p\u003e\n\u003ch3 data-end=\"11909\" data-start=\"11850\" data-section-id=\"ilef2q\"\u003e6.6 Special Precautions for Disposal and Other Handling\u003c\/h3\u003e\n\u003cp data-end=\"11935\" data-start=\"11911\"\u003eNo special requirements.\u003c\/p\u003e\n\u003ch2 data-end=\"11973\" data-start=\"11937\" data-section-id=\"kqpc63\"\u003e7. Marketing Authorization Holder\u003c\/h2\u003e\n\u003cp data-end=\"12082\" data-start=\"11975\"\u003e\u003cstrong data-end=\"11994\" data-start=\"11975\"\u003eIBSA PHARMA SAS\u003c\/strong\u003e\u003cbr data-end=\"11997\" data-start=\"11994\"\u003eParc de Sophia-Antipolis\u003cbr data-end=\"12024\" data-start=\"12021\"\u003eLes Trois Moulins, 280 Rue de Goa\u003cbr data-end=\"12060\" data-start=\"12057\"\u003e06600 Antibes\u003cbr data-end=\"12076\" data-start=\"12073\"\u003eFrance\u003c\/p\u003e\n\u003ch2 data-end=\"12123\" data-start=\"12084\" data-section-id=\"e0sc7x\"\u003e8. Marketing Authorization Number(s)\u003c\/h2\u003e\n\u003cp data-end=\"12200\" data-start=\"12125\"\u003e34009 302 811 7 8: box of 30 tablets\u003cbr data-end=\"12164\" data-start=\"12161\"\u003e34009 302 811 8 5: box of 90 tablets\u003c\/p\u003e\n\u003ch2 data-end=\"12262\" data-start=\"12202\" data-section-id=\"tijx3p\"\u003e9. Date of First Authorization \/ Renewal of Authorization\u003c\/h2\u003e\n\u003cp data-end=\"12300\" data-start=\"12264\"\u003eTo be completed later by the holder.\u003c\/p\u003e\n\u003ch2 data-end=\"12337\" data-start=\"12302\" data-section-id=\"1tj9ps9\"\u003e10. Date of Revision of the Text\u003c\/h2\u003e\n\u003cp data-end=\"12375\" data-start=\"12339\"\u003eTo be completed later by the holder.\u003c\/p\u003e\n\u003ch2 data-end=\"12393\" data-start=\"12377\" data-section-id=\"wci03x\"\u003e11. Dosimetry\u003c\/h2\u003e\n\u003cp data-end=\"12410\" data-start=\"12395\"\u003eNot applicable.\u003c\/p\u003e\n\u003ch2 data-end=\"12471\" data-start=\"12412\" data-section-id=\"ru3nal\"\u003e12. Instructions for Preparation of Radiopharmaceuticals\u003c\/h2\u003e\n\u003cp data-end=\"12488\" data-start=\"12473\"\u003eNot applicable.\u003c\/p\u003e\n\u003ch2 data-end=\"12531\" data-start=\"12490\" data-section-id=\"1ubbw2g\"\u003ePrescription and Dispensing Conditions\u003c\/h2\u003e\n\u003cp data-is-only-node=\"\" data-is-last-node=\"\" data-end=\"12578\" data-start=\"12533\"\u003eMedicine not subject to medical prescription.\u003c\/p\u003e","brand":"Pharmarcie.com","offers":[{"title":"Default Title","offer_id":46228459192492,"sku":"P3400930281185","price":149.97,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0604\/4047\/7868\/files\/apic10_5ec924f8-652b-46c6-b270-4d17a3ef67de.jpg?v=1778176123","url":"https:\/\/pharmarcie.com\/products\/chondrosulf-chondroitin-800mg-90-tablets","provider":"Pharmarcie.com","version":"1.0","type":"link"}